Skip to main content

Table 1 Demographic characteristics

From: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

  DEM-TACE B-TACE p
Patient number; nodule number N:127; N:191 N: 22; N: 35  
Age, year (mean value ± SD) 68.6 ± 10.9 65.9 ± 13.8 0.28
Sex (M/F) 112/15 19/3 0.8
Child pugh N (%)    0.9
 A5 55 (43.3%) 11 (50.0%)  
 A6 24 (18.9%) 4 (18.2%)  
 B7 38 (29.9%) 5 (22.7%)  
 B8 10 (7.9%) 2 (9.1%)  
BCLC N (%)    
 A 84 (66.1%) 10 (45.5%) 0.06
 B 43 (33.9%) 12 (54.5%)  
Etiology: N (%)    0.78
 HCV 66 (52%) 9 (41.0%)  
 HBV 22 (17.3%) 4 (18.2%)  
 Alcohol related cirrhosis 17 (13.4%) 5 (22.7%)  
 Cryptogenetic cirrhosis 14 (11%) 3 (13.6%)  
 NASH 8 (6.3%) 1 (4.5%)  
MELD: (mean value ± SD) 9.9 ± 2.0 10.0 ± 2.3 0.82
MELDNa: (mean value ± SD) 10.8 ± 2.6 10.8 ± 2.6 0.91
AFP serum level μg/L (median IC95%) 27.5 (1.1–3971) 6.4 (0.7–2599.0) 0.65
Indications for TACE    0.7
 Downstaging 20 (15.7%) 3 (13.6%)  
 Bridging 50 (39.4%) 7 (31.8%)  
 Palliative 57 (44.9%) 12 (54.6%)  
  1. DEM-TACE drug eluting embolics trans-arterial chemoembolization; B-TACE balloon occluded trans-arterial chemoembolization; SD standard deviation; M Male; F Female; BCLC Barcelona clinic liver cancer; HCV Hepatitis C virus; HBV Hepatitis B virus; NASH Non-alcoholic steatohepatitis; MELD Model for End-Stage Liver Disease; AFP α- fetoprotein